AB
CLDX icon

Amalgamated Bank’s Celldex Therapeutics CLDX Stock Holding History

Amalgamated Bank’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2,058
Closed -$56K – 1867
2025
Q4 		$56K Sell
2,058
-131
-6% -$3.45K ﹤0.01% 1802
2025
Q3 		$57K Hold
2,189
– – ﹤0.01% 1804
2025
Q2 		$45K Hold
2,189
– – ﹤0.01% 1849
2025
Q1 		$40K Buy
2,189
+7
+0.3% +$156 ﹤0.01% 1839
2024
Q4 		$55K Hold
2,182
– – ﹤0.01% 1814
2024
Q3 		$74K Hold
2,182
– – ﹤0.01% 1753
2024
Q2 		$81K Buy
2,182
+96
+5% +$3.62K ﹤0.01% 1761
2024
Q1 		$88K Sell
2,086
-2,620
-56% -$108K ﹤0.01% 1748
2023
Q4 		$187K Sell
4,706
-467
-9% -$13.7K ﹤0.01% 1809
2023
Q3 		$142K Hold
5,173
– – ﹤0.01% 1895
2023
Q2 		$176K Sell
5,173
-21
-0.4% -$708 ﹤0.01% 1868
2023
Q1 		$187K Sell
5,194
-1,050
-17% -$45.3K ﹤0.01% 1829
2022
Q4 		$278K Buy
6,244
+64
+1% +$2.29K ﹤0.01% 1727
2022
Q3 		$174K Buy
6,180
+69
+1% +$2.12K ﹤0.01% 1902
2022
Q2 		$165K Sell
6,111
-969
-14% -$28.1K ﹤0.01% 1960
2022
Q1 		$241K Sell
7,080
-556
-7% -$17.8K ﹤0.01% 1866
2021
Q4 		$295K Sell
7,636
-69
-0.9% -$3.01K ﹤0.01% 1830
2021
Q3 		$416K Buy
7,705
+704
+10% +$33K ﹤0.01% 1679
2021
Q2 		$234K Buy
+7,001
New +$192K ﹤0.01% 1980
2018
Q2 		– Sell
-1,141
Closed -$40K – 1740
2018
Q1 		$40K Sell
1,141
-28
-2% -$1.08K ﹤0.01% 1584
2017
Q4 		$50K Buy
1,169
+165
+16% +$7.07K ﹤0.01% 1613
2017
Q3 		$43K Buy
1,004
+6
+0.6% +$225 ﹤0.01% 1551
2017
Q2 		$37K Buy
998
+199
+25% +$8.8K ﹤0.01% 1557
2017
Q1 		$43K Hold
799
– – ﹤0.01% 1476
2016
Q4 		$42K Buy
799
+101
+14% +$5.75K ﹤0.01% 1488
2016
Q3 		$42K Buy
698
+3
+0.4% +$187 ﹤0.01% 1364
2016
Q2 		$45K Buy
695
+2
+0.3% +$127 ﹤0.01% 1358
2016
Q1 		$39K Buy
+693
New +$78K ﹤0.01% 1263
2015
Q4 		– Sell
-690
Closed -$109K – 1217
2015
Q3 		$109K Buy
690
+11
+2% +$3.11K 0.01% 1228
2015
Q2 		$257K Buy
679
+77
+13% +$30.6K 0.03% 1089
2015
Q1 		$251K Buy
+602
New +$215K 0.03% 768
2014
Q1 		– Sell
-581
Closed -$211K – 842
2013
Q4 		$211K Buy
+581
New +$224K 0.04% 745

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Amalgamated Bank's CLDX Position: Q1 2026 in Review

Amalgamated Bank sold out of Celldex Therapeutics (CLDX) in Q1 2026, closing a stake of 2,058 shares — an estimated $56K sold.

Amalgamated Bank first reported a position in CLDX in Q4 2013 and held it in 32 quarters. The position peaked at $416K in Q3 2021. 228 funds tracked by Wall St. Rank hold CLDX as of Q1 2026.

  • Amalgamated Bank reported no remaining Celldex Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Amalgamated Bank sold 2,058 Celldex Therapeutics shares in Q1 2026, an estimated $56K.
  • Amalgamated Bank first reported a position in Celldex Therapeutics in Q4 2013 and held it in 32 quarters.
  • Amalgamated Bank's Celldex Therapeutics position peaked at $416K in Q3 2021.
  • 228 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2026.

Based on Amalgamated Bank's 13F filing for Q1 2026, filed 8 May 2026.